Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes

This publication has 44 references indexed in Scilit:

• PPAR agonists in health and disease: a pathophysiologic and clinical overview
  Current Opinion in Endocrinology, Diabetes and Obesity, 2002
• Lipid-Lowering Drugs: Are Adverse Effects Predictable and Reversible?
  Cardiology, 2002
• Peroxisome Proliferator-activated Receptor-α Regulates Lipid Homeostasis, but Is Not Associated with Obesity
  Journal of Biological Chemistry, 2001
• Fenofibrate and Rosiglitazone Lower Serum Triglycerides with Opposing Effects on Body Weight
  Biochemical and Biophysical Research Communications, 2000
• The PPARs: From Orphan Receptors to Drug Discovery
  Journal of Medicinal Chemistry, 2000
• The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates
  Journal of Biological Chemistry, 1998
• Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)
  Journal of Biological Chemistry, 1998
• 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
  Cell, 1995
• Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
  Nature, 1990
• Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal β-oxidation in cultured rat, dog, and rhesus monkey hepatocytes
  Toxicology and Applied Pharmacology, 1990